Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
about
Advances in rheumatology: new targeted therapeuticsBiologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysisRituximab for rheumatoid arthritisOfatumumab for rheumatoid arthritisAdverse effects of biologics: a network meta-analysis and Cochrane overviewRituximab for rheumatoid arthritisBiologic interventions for fatigue in rheumatoid arthritisClinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early diseaseAnimal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive ReviewKey issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implicationsTowards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatmentCellular targeting in autoimmunityMy treatment approach to rheumatoid arthritisHumoral-targeted immunotherapies in multiple sclerosisUnderstanding the role of B cells in atherosclerosis: potential clinical implicationsMyalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristicsAdvances in the treatment of polyarticular juvenile idiopathic arthritisBiologic agents for rheumatoid arthritis--negotiating the NICE technology appraisalsThe effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responsesRegulation of B lymphocytes and plasma cells by innate immune mechanisms and stromal cells in rheumatoid arthritis.Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities.Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.Advances in the treatment of rheumatoid arthritis.Response to rituximab in patients with rheumatoid arthritis in different compartments of the immune system.New pharmacological strategies in rheumatic diseasesRituximab in autoimmune diseasesRituximab for Rheumatoid Arthritis.Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?The role of biologics in treatment of connective tissue disease-associated interstitial lung diseaseOcrelizumab: a step forward in the evolution of B-cell therapyRelationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patientsCausal modeling using network ensemble simulations of genetic and gene expression data predicts genes involved in rheumatoid arthritisCholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to Fab 2 fragmentsComparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression AnalysisIn vivo, multimodal imaging of B cell distribution and response to antibody immunotherapy in miceBiologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature.B cells and atherosclerosis.Clinical considerations for biosimilar antibodies.
P2860
Q21093257-C82A4CC5-ECAE-4E6F-942A-4641B678654DQ24185797-BEDDC43C-0E8E-4A67-9421-91A9C4A22508Q24186568-BDBE2023-357D-44E6-B8C3-70568EEDC295Q24202719-6174BC75-AADE-40DD-A8DD-1FE9DF71E68AQ24234197-9E82D1AE-A4A1-4DE8-A1BE-C3BD2B9D6604Q24242554-ED045DF4-D2BC-4947-9232-4F4E14972598Q26471538-1651E5DD-C4E9-4C7E-9A87-44D3543FF396Q26753120-7F41A371-35D1-469E-8DC0-A60528EB9EFDQ26774874-FB645573-0903-4C3D-ADE0-33189D11CCE4Q26775756-520C11FD-609D-4053-BE0E-7B9CFB9A5175Q26786705-2B39D3FE-B290-4ECD-BA67-449198F95F9FQ26824580-DF73FAB9-B401-4F34-A56F-8B6B9E2BAF70Q26829955-05038AC5-8706-49A0-8B52-6A9B06DE2AD5Q26865971-36831E8D-1744-4974-BA84-C3CF4DC6FD6FQ26991813-4FA93E85-26C4-4B01-9856-B2D964D740FEQ26998412-0DDF7E6E-B4AA-4606-BDA8-97E29E6D4ED0Q27001017-906430A2-6762-4EA9-856B-1B241AF71D98Q27010957-B4AEFFDE-349E-4D82-B03E-C396D9E55658Q27022645-81C790A0-33E1-4ED5-ADA4-96CF0270AAFFQ27686770-51EBC52D-8ED7-4D0D-BB2C-E8561F4E4D48Q27687777-8D502D1C-D9B7-433A-B703-507388057DF6Q27691388-36D103C1-9905-4D6A-8E89-D963E93953BDQ27691822-BC09E1D5-56FC-4B4F-BB20-D3A0078B99EEQ27692640-6AF141FE-70CD-4559-9275-212285FEB781Q28073763-C3259372-4D24-421C-8C09-82A80F61B454Q28076091-4EA803B1-D6F3-4EAC-848D-CFC2BB6D10C8Q28080246-C4C758EC-0E03-44EF-A4E2-D4871F7156ECQ28081034-A52700D9-36F3-48E3-A6C1-0159699C9FCFQ28082021-A63F672C-25FB-4413-85F6-C87499FDB15AQ28245986-AFB05A6B-16ED-45E5-A3F2-5D113A96060CQ28290930-5769E759-399D-431E-AA5C-D43E2AA77572Q28477388-0B9E5B0F-8617-4D1E-8771-70D4D9D03FC5Q28535018-11ED0981-5B5F-43C3-9FCD-DE882D9CF5E4Q28547851-0F238FFE-F68B-4F6B-B675-00561C59D6D3Q28752150-64074FAA-8838-49FC-8899-E5B10D08D28FQ30234528-236F64D8-C53C-416F-B663-1A701D0DB06FQ30235341-48A60779-EA06-4DF7-B3BE-9803E222CD2DQ30250242-93F43BC1-DAB4-4CEA-8E83-97982E77EBCFQ30252928-301096B7-D459-4799-9017-54BABA67354FQ30377239-44D315DE-A2E1-4010-9473-0578D783EEEC
P2860
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Rituximab for rheumatoid arthr ...... d safety at twenty-four weeks.
@en
Rituximab for rheumatoid arthr ...... d safety at twenty-four weeks.
@en-gb
Rituximab for rheumatoid arthr ...... d safety at twenty-four weeks.
@nl
type
label
Rituximab for rheumatoid arthr ...... d safety at twenty-four weeks.
@en
Rituximab for rheumatoid arthr ...... d safety at twenty-four weeks.
@en-gb
Rituximab for rheumatoid arthr ...... d safety at twenty-four weeks.
@nl
prefLabel
Rituximab for rheumatoid arthr ...... d safety at twenty-four weeks.
@en
Rituximab for rheumatoid arthr ...... d safety at twenty-four weeks.
@en-gb
Rituximab for rheumatoid arthr ...... d safety at twenty-four weeks.
@nl
P2093
P2860
P50
P356
P1476
Rituximab for rheumatoid arthr ...... d safety at twenty-four weeks.
@en
P2093
Edward C Keystone
Eva W Hessey
James E Loveless
Maria W Greenwald
Mark C Genovese
Mark C Totoritis
Matthew W Cravets
REFLEX Trial Group
Richard A Furie
Stanley B Cohen
P2860
P304
P356
10.1002/ART.22025
P577
2006-09-01T00:00:00Z